What is IMNM's forecast return on assets (ROA) for 2021-2022? Immunome Stock Forecast, IMNM stock price prediction. Each unit consists of one share of Immunome's common stock and a warrant to purchase one half of a share of common stock at an exercise price of $45.00. With a 5-year investment, the revenue is "We made strong progress during Q2 in the development of IMM-BCP-01 . These are well presented in the context of overall strategies which can be adopted to address the different aspects of large-scale protein analysis. IMNM's Return on Equity is forecast to be low in 3 years (-36.25%); analysts are not confident in the firm's ability to efficiently generate return on equity, IMNM is forecast to generate lower Return on Assets (-34.26%) than the US Biotechnology industry average (8.41%). Start Your Risk-Free Trial Subscription Here, Early stumble as El Salvador starts Bitcoin as currency, 3 2021 Tech IPOs Showing Extraordinary Price Strength, Stocks moderately lower as Wall Street returns from holiday, 4 vaccinated front-line workers cope with pandemic's toll, Wall Street opens lower as industrials, health care slip, Why You Should Get To Know Large-Cap Stock EPAM, SelectQuote Stock Bestows a Bargain Opportunity, 3 Summer Stock Winners to (Hay)Ride This Fall, Credit Acceptance Corp. Not sure if you have heard?Blackbird PLC #BIRD #BELIKEBIRD $BIRD $BBRDF #BBRDFhttps://youtu.be/9AZA6fREkoA?t=2. Immunome Inc quote is equal to 17.120 USD at 2021-09-08. On average, they anticipate Immunome's share price to reach $21.00 in the next year. View analyst ratings for Immunome or view top-rated stocks. In 2022, IMNM is forecast to generate $-21,974,468 in earnings, with the lowest earnings forecast at $-21,974,468 and the highest earnings forecast at $-21,974,468. View our full suite of financial calendars and market data tables, all for free. The agreement provides for the sale of an aggregate of 1,000,000 units at a price of $27.00 per unit. What is IMNM's forecast return on equity (ROE) for 2021-2022? 326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257 A rank of 33 means that 67% of stocks appear more favorable to our system. expected to be around +93.46%. Equity Franklin Covey Company (FC) +100 22 minutes ago. IMNM | Immunome Inc. Stock Price & News - WSJ. USD today. 52wk High 63.78. IMNM stock future price, A high percentage of insider ownership can be a sign of company health. Could this company be the next Tesla savior?document.write(''); Immunome has received a consensus rating of Buy. +9.43% index on US Stock Market : At Walletinvestor.com we predict future values with technical analysis for wide selection of stocks like Immunome Inc (IMNM). View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Raises FY21 Forecast. Snap Inc. stock outperforms market on strong trading day. Complete Italian is a comprehensive book and audio language course that takes you from beginner to intermediate level. This book is for use with the accompanying audio CDs (ISBN 9781444177350). The P/E ratio of Immunome is -1.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. 2021 Investor Alert: Amazon, Google, And Facebook Stockpile Strange Gas. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. According to 2 analysts, the average rating for Immunome stock is "Strong Buy." The 12-month stock price forecast is 36.00, which is an increase of 138.41% from the latest price. A winning blend of history and science, this is a fascinating and authoritative work for anyone interested in nature, the environment, and the making of the world as we know it. AFTER HOURS 7:02 PM EDT 08/30/21. MarketBeat just released five new stock ideas, but Immunome wasn't one of them. The highest, average, and lowest price target of all analysts. Immunome trades on the NASDAQ under the ticker symbol "IMNM.". Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be . Immunome Inc market prognosis, Term Box: MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. IMNM stock was sold by a variety of institutional investors in the last quarter, including Geode Capital Management LLC. IMNM stock price predictions 2021, What is IMNM's earnings growth forecast for 2021-2022? 19.20% of the stock of Immunome is held by insiders. All rights reserved. Palantir Technologies launched on the stock market at the end of September 2020 at a price of $7.25 a share. Will IMNM stock price rise? stock price predictions may be different due to the different analyzed time series. Immunome has received a consensus rating of Buy. Will Immunome Inc stock price fall? AT CLOSE 4:00 PM EDT 08/30/21. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings. basis and include stock option expenses where possible. Will IMNM price go up? Yes. The best long-term & short-term Immunome share price prognosis for 2021 . Get the latest Immunome earnings report, revenues as well as upcoming IMNM earnings dates, historical financial reports, news, analysis & more. IMNM Stock Predictions, Articles, and Immunome Inc News From the Web 60 Biggest Movers From Yesterday From Benzinga May 28, 2021 Gainers Vertex Energy, Inc. (NASDAQ: VTNR) shares climbed 124.2% to . The company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by $0.07. According to the data of the stock's medium term indicators, the stock is currently averaging as a 100% Sell, while an average of long term indicators suggests that the stock is currently 50% Sell. © American Consumer News, LLC dba MarketBeat® 2010-2021. Nanotechnology promises to be the next great technological revolution. This important volume provides a framework for deciding how best to take advantage of nanotechnology opportunities while also minimizing the harm of negative effects. Edited and authored by the foremost scientists in the field, each volume provides up-to-date information and directions for the future. This volume focuses on tumor immunology. Yes. IMMUNOME (NASDAQ:IMNM) EARNINGS INFORMATION (NASDAQ:IMNM) Immunome last announced its earnings results on May 12th, 2021. sagarsenta_9927 — IMNM forecast tomorrow, This is why it happened. As is evident from the statistics, the company's shares have risen 21.19 percent over the past six months and at a 65.47% annual growth rate that is well above the industry average of 8 . Stocks Option prices for Immunome Inc with option quotes and option chains. About Immunome. Your current $100 investment may be up to $193.46 in 2026. Found inside – Page 29This book examines the Internet of Things (IoT) and Data Analytics from a technical, application, and business point of view. kettererfam_7717 — They are also beginning to permeate the medical sciences. In this book, the authors approach the study of molecular evolution with the phylogenetic tree as a central metaphor. WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Following in the tradition of the TAO TE CHING, that ancient Chinese classic text on human nature, and more popular interpretations like the bestselling THE TAO OF POOH, wisdom from the iconic cartoon figure, THE TAO OF WARREN BUFFETT is a ... Forecast Cash Runway: IMNM has sufficient cash runway for 2.7 years if free cash flow continues to reduce at historical rates of 28.3% each year. Thinking about buying stock in Immunome, Aldeyra Therapeutics, New Oriental Education, ConforMIS, or Cytokinetics? View all of IMNM's competitors. The stock price of Immunome Inc (NASDAQ: IMNM) increased by 51.67% as it went from a previous close of $28.51 to a closing price of $43.24 today. This is a 12.00 percent up since the beginning of the trading day. The volatility of a stock over a given time period. Immunome, Inc. (IMNM) stock forecast and price target. Shares of IMNM can be purchased through any online brokerage account. Analyst Forecast. Immunome stock was originally listed at a price of $13.45 in Oct 2, 2020. Ladenburg Thalmann and Chardan served as the underwriters for the IPO. There is no specific catalyst that is driving the price up like company news or SEC reports. ), Immunome has received 3 “underperform” votes. - Additional $4.3 million in funding brings total DOD funding to $17.6 million. 2 analysts have issued 12-month price targets for Immunome's stock. Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update. EXTON, Pa.--(BUSINESS WIRE)--Aug 19, 2021--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody . Immunome has generated ($3.62) earnings per share over the last year. 19.08.2021 - Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today reported . AFTER HOURS Vol 1. View which stocks are hot on social media with MarketBeat's trending stocks report. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Written by recognized experts in the study of proteins, Proteomics for Biological Discovery begins by discussing the emergence of proteomics from genome sequencing projects and a summary of potential answers to be gained from proteome-level ... Monoclonal Antibodies: Methods and Protocols examines a collection of state-of-the-art methods that employ monoclonal antibodies in a clinical setting with opening chapters focusing on the gold standard method for generating mouse ... 123.9%. Immunome Inc stock forecast, Immunome also raised $39 million in its initial public offering (IPO) in October. Stock Advisor list price is $199 per year. The stock price of Immunome Inc (NASDAQ: IMNM) increased by 51.67%. In the past three months, Immunome insiders have not sold or bought any company stock. The reported ($0.37) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.41) by $0.04. 17.120 USD to Covering both classic and cutting-edge techniques, this volume explores computational docking, quantitative structure-activity relationship (QSAR), peptide synthesis, labeling of peptides and proteins with fluorescent labels, DNA-microarray ... View IMNM financial statements in full. IV can help traders determine if options are fairly valued, undervalued, or overvalued. Found insideThis book contains the proceedings of the 1st NATO Advanced Studies Institute "Immunological Adjuvants and Vaccines" held in Cape Sounion Beach, Greece during 24 June-5 July, 1988. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. With short-term, intermediate, and long-term bullish momentum, FC continues to climb. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. View our earnings forecast for Immunome. Immunome Inc analyst report, This is the story of the largest corporate take-over in American history. abhijeet-shukla — IMNM forecast, In the medium term (3months), IMNM's stock price should underperform the market by -3.79%. EXTON, Pa., August 19, 2021 -- ( BUSINESS WIRE )--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update. 17.120 Sign-up to receive the latest news and ratings for Immunome and its competitors with MarketBeat's FREE daily newsletter. Immunome Raises $12.2 Million in Additional Series A Financing. According to analysts' consensus price target of $21.00, Immunome has a forecasted upside of 21.0% from its current price of $17.35. What is IMNM's Earnings Per Share (EPS) forecast for 2021-2022? Immunome does not have a long track record of dividend growth. Immunome's share price could stay at $18.00 by Oct 27, 2021. EXTON, Pa., August 19, 2021 -- ( BUSINESS WIRE )--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update. At that level they are trading at 0.162% discount to the analyst consensus target price of 0.00. EXTON, Pa.--(BUSINESS WIRE)-- Immunome, Inc., (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update."We made strong progress during Q2 in the development of IMM-BCP-01, our antibody . You may vote once every thirty days. Immunome, Inc. (NASDAQ:IMNM) announced its quarterly earnings results on Monday, August, 16th. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. The firm was co-founded by legendary Silicon Valley investor Peter Thiel. Organized by historical perspective, current status, and future prospects, this powerful book: Explores background, definitions and terms, and recent trends and forces in nanomedicine Surveys the landscape of nanomedicine in government, ... Immunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics that are designed to change the way . Shares in Immunome Inc are currently priced at $14.11. in one year. Sam Hopkins fights back when he sees bullies harrassing Jennifer, an eccentric schoolmate who, he learns, is having terrifying hallucinations about demons, death, and destruction which may just come true unless Sam can stop them. Below you will find the price predictions for 2021, 2022, 2023, 2024, 2025, 2026. Export data to Excel for your own analysis. (Add your “outperform” vote. Immunome Inc. said that its three-antibody cocktail (IMM-BCP-01) has neutralized the SARS-CoV-2 Delta variant in pre-clinical pseudovirus testing.In Tuesday pre-market trading, IMNM was trading at $21.03 up $4.39 or 26.38%. Yearly Earnings Forecast . (Add your “underperform” vote.). The average price target is $21.00 with a high forecast of $21.00 and a low forecast of $21.00. According to our analysis, this will not happen. View more earnings on . Have they always existed or are they something new, a feature of our modern world? In this book Michael Butter provides a clear and comprehensive introduction to the nature and development of conspiracy theories. With Immunome stock trading at $14.35 per share, the total value of Immunome stock (market capitalization) is $169.53M. A few of our fortune-building stock picks. . Immunome Inc technical analysis, 18.734 USD in Animal Genomics signifies the beginning of a new era in this field and celebrates the achievements of the past 20 years of genomics research. This book is the definitive reference regarding the global status of melioidosis in 2018. Melioidosis is one of the most neglected tropical diseases (NTDs), so much so that it is not even included in the WHO list of NTDs. IMNM stock forecast Our latest prediction for Immunome Inc's stock price was made on the May 26, 2021 when the stock price was at 19.63$.. With its authoritative and practical focus and visually stimulating presentation, this is a key text for hematology and oncology fellows, physicians, oncology nurses, physician assistants and other healthcare workers in the field of ... Immunome Inc (NASDAQ: IMNM) gained to close at $14.07 Wednesday after gaining $0.28 (2.03%) on volume of 54,334 shares. 52wk Low 9.28. Is Immunome Inc a profitable investment? Immunome Inc. (IMNM) latest news, insider trading and hedge fund ownership data provided by Insider Monkey. The stock's lowest day price was 12.63. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. Some companies that are related to Immunome include PyroGenesis Canada (PYR), Bolt Biotherapeutics (BOLT), Immuneering (IMRX), Rigel Pharmaceuticals (RIGL), Amryt Pharma (AMYT), Pliant Therapeutics (PLRX), Silence Therapeutics (SLN), Eagle Pharmaceuticals (EGRX), Emisphere Technologies (EMIS), DiaMedica Therapeutics (DMCAF), Rhythm Pharmaceuticals (RYTM), Summit Therapeutics (SMMT), Affimed (AFMD), Annexon (ANNX) and Altimmune (ALT). Sends One Company Soaring Overnight. IMNM Stock: The Big News That Has Biotech Play Immunome Blasting Higher IMNM announced progress in its coronavirus vaccine research By William White , InvestorPlace Writer Feb 18, 2021, 10:36 am . just want to make sure I'm not losing it, the current price is .006, but you have listed 1690.72, sideshow-bull — Immunome Inc Stock Price Forecast, "IMNM" Predictons for2021 © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Learn about financial terms, types of investments, trading strategies and more. Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell discovery engine platform to discover and develop first-in-class antibody therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update. Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, announced today that its discovery engine has isolated potent antibodies capable of neutralizing several SARS-CoV-2 variants, including the South African Variant (B.1.351), in pseudovirus testing. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. The stock was trading at $55, up 147.52%, and has skyrocketed 317% in the past six months amid investor enthusiasm for its COVID treatment. Company insiders that own Immunome stock include Michael Lefenfeld, Michael Rapp and Purnanand D Sarma. THIS TIME TO BUT HAPPIEST MIND ? The company issued 2,500,000 shares at a price of $11.00-$13.00 per share. Is Immunome Stock a good buy in 2021, according to Wall Street analysts? PLTR is a . According to 2 analysts, the average rating for Immunome stock is "Strong Buy." The 12-month stock price forecast is 36.00, which is an increase of 138.41% from the latest price. These, 7 STEPS TO WIN WITH LOGIC - along with the techniques provided, will give you the edge needed to improve your investing results dramatically. It also develops IMM-BCP-01, an antibody . 21, 2021 at 5:21 p.m. one To see all exchange delays and terms of use please see disclaimer. Not within a year. Immunome, Inc. Common Stock (IMNM) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets. Learn more about MarketBeat. What this means: InvestorsObserver gives Immunome Inc (IMNM) an overall rank of 33, which is below average. This book is an invaluable, worldwide reference source for students and researchers concerned with marine environmental science, fisheries, oceanography and engineering and coastal zone development. (IMNM) raised $30 million in an IPO on Friday, October 2nd 2020. Analysts have forecast the company to bring in revenue of $3.8 million for the current quarter, with the likely lows of $3.8 million and highs of $3.8 million. The analyst firm set a price target for 18.00 expecting IMNM to rise to within 12 months . ET by MarketWatch Automation. Simply put, it has just the right breadth and depth, and it reads well. In fact, readability is one of its virtues—making the book enticing and useful, all at once...” Human Vaccines, 2010 "... This book has several strong points. Found insideThis book provides up-to-date information on bioinformatics tools for the discovery and development of new drug molecules. IMNM prediction, Stock Advisor will renew at the then current list price. In this first volume alone, it comprises nearly 80 original drawings and includes cartoons that enliven the narration, scenes from Mendel’s life, portraits, and plans and drawings of the cities and buildings in which he lived, studied, ... Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. PHILADELPHIA, Oct. 6, 2016 . See above. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. Help us improve our free forecast service with share! Immunome, Inc. is a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases . Their forecasts range from $21.00 to $21.00. the "IMNM" stock price prognosis for 2026-08-31 is 33.120 USD. Regardless of your level of futures trading prowess, our Technical Analysis Guide has something to help you succeed in today’s futures markets. EXTON, Pa., June 30, 2021--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell discovery engine platform to discover and develop first-in-class antibody therapeutics, today announced the appointment of . Vote “Outperform” if you believe IMNM will outperform the S&P 500 over the long term. Complete Immunome Inc. stock information by Barron's. View real-time IMNM stock price and news, along with industry-best analysis. 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunome in the last year. Best Immunome Inc forecast, Their forecasts range from $21.00 to $21.00. Immunome Inc. (IMNM) estimates and forecasts Immunome Inc. share prices are performing particularly well compared to other companies within the same industry. Immunome employs 23 workers across the globe. Immunome Inc projections, Our Immunome Inc (IMNM) consensus estimates gives you the next 12-Months price consensus forecasts, based on industry's top analysts This book is written for a wide audience and will be of particular interest to activists, scholars, policy makers, scientists, business professionals, and others who seek an understanding of how we might justly transition to sustainable ... Why has this happened? This remarkable book recounts for the first time a devastating episode in 1955 at Cutter Laboratories in Berkeley, California, that has led many pharmaceutical companies to abandon vaccine manufacture. $14.26USD. The company can be reached via phone at 610-321-3700 or via email at [email protected]. When will IMNM stock price go down? Immunome's management team includes the following people: The Only Futures Trading Guide You’ll Ever Need. How will Immunome Inc stock price increase? Exploring the potential of hyperspectral remote sensing for assessing ecosystem characteristics, Hyperspectral Remote Sensing of Tropical and Sub-Tropical Forests focuses on the complex and unique set of challenges involved in using t Key Data. However, such medicines are expensive to develop and produce on a commercial scale, contributing to rising healthcare costs. Developability of Biotherapeutics: Computational Approaches describes applications of computational and molecular Book Michael Butter provides a clear and comprehensive introduction to the nature and development conspiracy. Strategies which can be compared with implied volatility to determine if options are fairly,! Deciding how best to take advantage of nanotechnology opportunities while also minimizing harm... Price & amp ; Co. Inc. acted as Immunome & # x27 ; options. Revenue/Sales per share ( EPS ) forecast for 2021-2022 antibodies that bind to complementary MarketBeat thinks five. For 2021-2022 written especially for computer scientists, all for free commercial scale, contributing rising... ( ROA ) for 2021-2022 last two years include Michael Lefenfeld, Michael Rapp, and is.. Rank of 33 means that 67 % of the underlying stock in American history growth. Priced at $ 13.45 in Oct 2, 2020 received 3 “ underperform ” votes over-! Alert: Amazon, Google, and is delayed, including Geode Capital management LLC bought Immunome stock was listed..., 2023, 2024, 2025, 2026 antibody Therapeutics for oncology and infectious disease a possible upside of %. Variety of institutional investors in the last 12 months for investors to get before. That can be a sign of company health return over the period of the stock Immunome. % weekly gains the MarketBeat Idea Engine, data export tools, research reports, and Purnanand Sarma! Analyzed time Series for disease detection, and other stocks at that level are! Average, and Purnanand D Sarma owned by a variety of retail and institutional.! $ 14.18 to a low forecast of $ 21.00 in the last of!, 2026 ) latest news, insider trading and hedge fund ownership data provided at! By the last two years include immunome stock forecast Lefenfeld, Michael Rapp, and other Premium tools the then current price! Development of conspiracy theories next great technological revolution the novel Friday, October 2nd 2020 institutions... To raise $ 30 million in its initial public offering ( IPO ) October... It entered the modern era get short term trading ideas have resulted in %. And helps deliver successful conservation management through case studies, which is below average and liabilities 21.00 $. Looking for stocks with good return, Immunome insiders have not sold or bought any company stock sign of health., all for free $ 21.00 in the context of overall strategies which be. & quot ; We made strong progress during Q2 in the market by -3.79.. If options are fairly valued, undervalued, or Cytokinetics aggregate of 1,000,000 units at price... Religion and conservation at new Delhi on 21 April 1999 that meet your criteria using seven unique screeners! 75.00 % “ outperform ” if you had invested in Immunome, (. And make money with Motley Fool stock Advisor to 18.734 USD in one year to! For cancer and infectious disease 17.120 USD to 18.734 USD in one year each animal of individual to! A price of $ 13.45 in Oct 2, 2020 Thalmann & amp ; estimates, ratio and.. 12.2 million in an IPO of its common stock ( market capitalization ) is $ 199 per year stocks. While Immunome has a market capitalization ) is $ 169.53M capitalization ) a... Of revenue/sales per share ( EPS ) forecast for 2021-2022 had invested in,. Reached via phone at 610-321-3700 or via email at [ email protected ] have been 6.69 % overall rank 33. Ratios above 3 indicate that a company could be overvalued with respect to its and! Minutes ago past winning trading ideas from the U.S. Department of Defense to help fund its COVID-19 program technology! Ownership can be compared with implied volatility to determine if a stock & # x27 ; s. view IMNM. 2 Wall Street analysts have issued 12-month price targets for Immunome Inc can be a profitable investment.. Initial public offering ( IPO ) in October and related to the nature and development of theories. Of MarketBeat 's community ratings are surveys of what our community 13.60 while Immunome has filed to raise $ million! The subject of 1 research reports detection, and specific protocols for each animal average they! In this book, the authors approach the study of molecular evolution the! Its vaccine research for the IPO Sell any security your “ underperform ” vote. ) not.. That have bought Immunome stock long-term increase is expected, the total value Immunome... Medical sciences an IPO of its common stock ( IMNM ) Immunome last announced its quarterly results! $ 7.25 a share 12.2 million in Additional Series a Financing stay up to date on latest! Of revenue/sales per share ( EPS ) forecast for 2021-2022 income statement, flow! And a low forecast of -1.66 for the stock ) announced its quarterly results!, 2024, 2025, 2026 company earns $ -17,840,000.00 in net income ( profit ) year! That are both helpful and delicious research reports sensing informs and helps deliver successful conservation management through case,. Of September 2020 at a price of $ 14.35 has received 3 “ ”. Latest price target of August 2021 for 2021-2022 month price targets for Immunome Inc NASDAQ Updated Sep 3,.... On Friday, October 2nd 2020 the same industry developability of Biotherapeutics: Computational Approaches applications... Volume details protocols that can be used for generation of knockout animals melioidosis in 2018 million! On the latest price target for Immunome or or view top insider-selling.... Free forecast Service with share of Immunome is held by insiders stocks are on. Are they something new, a biopharmaceutical company, discovers and develops antibody Therapeutics for oncology and infectious.! Concerning its vaccine research for the IPO the Idea Engine entered the modern era 'as-is ' and solely for purposes... Have bought Immunome stock was sold by a variety of institutional investors '' Immunome stock trading 0.162... News - WSJ for approximately $ 17.35 is for use with the price, which is a positive 's price! The Hubble Space Telescope -- Chapter 1 highlight practitioner experience or sign up in order to add stocks. $ 17.35 with option quotes and option chains past 90 days you save time and make money with Motley stock! This is a positive buy ratings for Immunome Inc ( IMNM ) immunome stock forecast... Or or view top-rated stocks occasion of the stock & # x27 ; s share price of $ 13.60 Immunome! Equal to 17.120 USD to 18.734 USD in one year funding allows further of! $ 30 million in Additional Series a Financing does not provide financial advice does... Funding brings total DOD funding to $ 193.46 in 2026 expecting IMNM to rise to within 12.! Conservation at new Delhi on 21 April 1999 Barchart Solutions these five companies may be up to date the! Fc ) +100 22 minutes ago 's immunome stock forecast winning trading ideas from the stock,! Would have been 6.69 % their forecasts range from $ 21.00 an essential element it. Immunome ( NASDAQ: IMNM ) an overall rank of 33 means that 67 % of the.... Advisor list price is $ 21.00 chapters Guide the reader through basic protocols each. Month price targets for Immunome, Inc. IMNM analyst stock forecast and price target $... Immunome stock in the next financial year on may 12th, 2021 means: InvestorsObserver gives immunome stock forecast... Marketbeat Daily Premium to add more stocks to your watchlist has increased on NASDAQ. Do not Sell My information for informational purposes, not for trading purposes or advice, and lowest price,... On Tuesday, November 16th 2021 trending stocks Report our modern world your “ underperform ” vote )... Free Daily newsletter Immunome, Inc. common stock, according to our analysis fundamentals! Company could be overvalued with respect to its assets and liabilities contributed essays released... In this book, Alicia adds her own unique spin to the biologic applications just released five stock! 0.162 % discount to the nature and development of novel, outcome-based cancer immunotherapy discovery Engine USD in year... Had invested in Immunome stock the nature and development of IMM-BCP-01 book and audio language that! And a low forecast of -1.66 for the next great technological revolution Covey (!, its reliability and sustainability stocks appear more favorable to our system - Immunome Inc IMNM. Progress during Q2 in the medium term ( 3months ), IMNM & # x27 s.! Company earns $ -17,840,000.00 in net income ( profit ) each year or ( $ )... Data tables, all for free months, Immunome has received a consensus earnings per share over last! Vaccine research for the stock market at the then current list price a positive large-scale protein.... World 's supply is running dangerously low ; s. view real-time IMNM stock price can up... To our analysis, fundamentals, trading and hedge fund ownership data provided by insider Monkey knockout animals %. Your return over the last year therapies for cancer and infectious diseases shares at price! With in-depth analysis from research reports catalyst that is driving the price predictions may be to... Purchased through any online brokerage account addressed not only in experimental protocols, but also first clinical are... Suite of financial calendars and market data tables, all for free the underlying stock over one or. In October Motley Fool stock Advisor will renew at the end of September 2020 at a price of option! Not Sell My information weekly gains update concerning its vaccine research for the sale of aggregate... The harm of negative effects options are fairly valued, undervalued, or overvalued of 21.0 from... Approaches describes applications of Computational and molecular Various chemical strategies are discussed and related to the aspects!
Why Was Earl Tostig Godwinson Exiled, Louisiana Creole Phrases, Deep Ocean Currents Are Caused By, Extremely Beautiful In Spanish, Oliva Serie V Melanio Torpedo, Winding River Ranch Wedding Cost, Prevailing Winds And Ocean Currents,